Updates are available Correction dated 2021-10-07
Click to view Correction: https://doi.org/10.1038/s42255-021-00476-7
-
Authors
Islam, Mohammad R.
Valaris, Sophia
Young, Michael F.
Haley, Erin B.
Luo, Renhao
Bond, Sabrina F.
Mazuera, Sofia
Kitchen, Robert R. https://orcid.org/0000-0003-1443-8559
Caldarone, Barbara J.
Bettio, Luis E. B.
Christie, Brian R. https://orcid.org/0000-0002-6830-0160
Schmider, Angela B.
Soberman, Roy J.
Besnard, Antoine https://orcid.org/0000-0002-0929-8873
Jedrychowski, Mark P.
Kim, Hyeonwoo
Tu, Hua
Kim, Eunhee
Choi, Se Hoon
Tanzi, Rudolph E. https://orcid.org/0000-0002-7032-1454
Spiegelman, Bruce M. https://orcid.org/0000-0002-7658-4802
Wrann, Christiane D. https://orcid.org/0000-0001-6066-8799
- License Information
-
More Information
Article History
Received: 12 February 2021
Accepted: 13 July 2021
First Online: 20 August 2021
Change Date: 7 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42255-021-00476-7
Competing interests
: The authors declare the following competing interests: B.M.S. and C.D.W. hold a patent related to irisin (WO2015051007A1). B.M.S. and C.D.W. are academic co-founders and consultants for Aevum Therapeutics. C.D.W. has a financial interest in Aevum Therapeutics, a company developing drugs that harness the protective molecular mechanisms of exercise to treat neurodegenerative and neuromuscular disorders. C.D.W.’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies. The other authors declare no competing interests.
